Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over (TA1147)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 April 2026
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over (TA977)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2024
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 March 2016Published: 26 April 2001
Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2008
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 June 2007